Patient B was a 54-year-old non-diabetic female with a history of re-entry tachycardia for which she was treated with ablation. She was hospitalized for hypoglycaemia 3 weeks after starting gabapentin in a dose reducing schedule for pain after surgery for a cervical herniated nucleus pulposus. The duration of hypoglycaemia was 2 days with a minimum blood glucose value of 1.3 mmol l −1 . After withdrawal of gabapentin and treatment with intravenous glucose she recovered. No concomitant medication was reported.
Information regarding four additional cases, including a causality assessment based on the Naranjo criteria [4] , is described in Table 1 . Previously, one case report was published describing hypoglycaemia in relation to gabapentin use. This concerned a 58-year-old non-diabetic female with end stage renal disease who had been on peritoneal dialysis for 6 years [3] . She received 4200 mg of gabapentin weekly for neuropathic pain, where 900 mg weekly was recommended for patients undergoing haemodialysis. Nadir blood glucose was 1.9 mmol l −1 which was corrected with dextrose. The patient recovered 3 days after withdrawal of gabapentin. Although renal failure is associated with hypoglycaemia, other causes were ruled out by the authors.
Although a mechanism for gabapentin-induced hypoglycaemia has not been established, two possibilities could be considered. First, GABA is present in the cytoplasm, insulin granules and microvesicles of the β-cells of the pancreas and can bind to the GABAA and GABAB receptor. Activation of the GABAB receptor is thought to inhibit insulin secretion whereas activation of the GABAA receptor leads to membrane depolarization and subsequent calcium influx, allowing the release of insulin [5] . Hypothetically, gabapentin-induced GABAA receptor activation could stimulate insulin release resulting in hypoglycaemia. Alternatively, direct binding to the alpha2-delta2 receptor of the voltage-gated calcium channels could also provide a pharmacological explanation. There are different varieties of this type of calcium-channel, consisting of several combinations of α1, β, α2-δ and γ subunits. Gabapentin has been shown to bind directly to the α2-δ1 and α2-δ2 subunit of the voltage-gated calcium channels [6] . The former is probably responsible for the neuronal activity of gabapentin, whereas the latter is found in, among others, the pancreas [7] . As with GABAA receptor activation, binding to the α2-δ2 subunit could result in calcium influx and subsequent insulin release.
In conclusion, these cases suggest that hypoglycaemia can occur in both diabetic and non-diabetic patients using gabapentin, possibly through GABAA receptor activation or binding to the α2-δ2 subunit of pancreatic voltagegated calcium channels. In our opinion, patients using gabapentin who experience symptoms indicative of hypoglycaemia should be examined accordingly.
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